Improving blood flow and insulin response in type 2 diabetes
Official title: Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes
Funded at University of Missouri-Columbia · NIH-11043325 · Data updated 2026-11-12
This study is looking at how a protein called ADAM17 affects blood flow and insulin response in people with type 2 diabetes, to see if blocking this protein can help improve blood sugar control and lower heart risks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $613,392 |
| NIH project number | 5R01HL151384-05 |
| Project ID | NIH-11043325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with type 2 diabetes who experience issues with insulin response and blood flow.
✕Less likely to help
Patients without type 2 diabetes or those with other underlying conditions affecting vascular health may not benefit from this research.
What this research studies
This research investigates how targeting a specific protein, ADAM17, can improve blood flow and insulin response in patients with type 2 diabetes. The study aims to understand the mechanisms that lead to reduced blood flow and glucose uptake in these patients. By exploring the role of ADAM17 in insulin signaling, the researchers will test whether a compound that inhibits ADAM17 can enhance vascular insulin sensitivity. This could lead to new treatment strategies for managing blood sugar levels and reducing cardiovascular risks associated with diabetes.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for type 2 diabetes that enhance blood flow and glucose control.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways to improve insulin sensitivity, suggesting potential for success in this approach.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Martinez-Lemus, Luis a — University of Missouri-Columbia
- Study coordinator: Martinez-Lemus, Luis a
Related research
Other NIH-funded projects on the same topics.
-
How pancreatic alpha cells respond in insulin resistance and type 2 diabetes
This project looks at why pancreatic alpha cells release too much glucagon in adults with insulin resistance or type 2 diabetes.
-
Investigating how muscle cells behave in insulin resistance and type 2 diabetes
This study is looking at how changes in muscle cells can make it harder for people with type 2 diabetes to use insulin properly, and it hopes to find new ways to help improve insulin sensitivity for better blood sugar control.
-
Understanding how pancreatic alpha cells respond to insulin resistance and type 2 diabetes
This study is looking at how certain cells in the pancreas behave when someone has type 2 diabetes, especially when the body struggles to use insulin properly, and it aims to find new ways to help manage diabetes better.
-
Using a natural compound to improve insulin sensitivity in type 2 diabetes
This study is looking at a new treatment for type 2 diabetes that targets a protein called galectin-3, using a natural compound called TFD100, to help improve insulin resistance and potentially offer a new option for managing the condition.
-
Subtyping Core for Research on the Causes of Type 2 Diabetes (SCORE-T2D)
A new U01 grant from a university research team aims to understand why Type 2 diabetes differs so much between people and how to tailor prevention and treatment.
-
Michigan Diabetes Project: A Peer-Led Self-Management Program for Adults with Type 2 Diabetes
A peer-led self-management program for adults with type 2 diabetes is being tested to see if it improves blood sugar control and daily diabetes care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.